Misplaced Pages

Zastaprazan: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyNext edit →Content deleted Content addedVisualWikitext
Revision as of 18:57, 23 December 2024 editInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,049 edits new page  Revision as of 19:01, 23 December 2024 edit undoCitation bot (talk | contribs)Bots5,420,675 edits Add: pmid, pages, issue, volume, journal, date, title, authors 1-5. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webformNext edit →
Line 59: Line 59:
}} }}


'''Zastaprazan''' (trade name '''Jaqbo''') is a pharmaceutical drug for gastrointestinal disorders. It is classified as a ].<ref>{{cite journal | doi = 10.1002/psp4.13228 }}</ref><ref>{{cite journal | doi = 10.1080/17425255.2024.2397433 }}</ref> In April 2024, it was approved for use in South Korea for the treatment of erosive ] (GERD).<ref>{{Cite journal | doi = 10.1007/s40265-024-02057-w }}</ref> In addition, it is Phase III clinical trials for ] and ].<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800044958 | title = Zastaprazan | publisher = AdisInsight }}</ref> '''Zastaprazan''' (trade name '''Jaqbo''') is a pharmaceutical drug for gastrointestinal disorders. It is classified as a ].<ref>{{cite journal | doi = 10.1002/psp4.13228 | title = Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers | date = 2024 | last1 = Yang | first1 = Eunsol | last2 = Hwang | first2 = Inyoung | last3 = Ji | first3 = Sang Chun | last4 = Kim | first4 = John | last5 = Lee | first5 = Seunghwan | journal = CPT: Pharmacometrics & Systems Pharmacology | volume = 13 | issue = 12 | pages = 2150–2158 | pmid = 39268835 }}</ref><ref>{{cite journal | doi = 10.1080/17425255.2024.2397433 | title = Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease | date = 2024 | last1 = Tietto | first1 = Angela | last2 = Faggin | first2 = Sofia | last3 = Scarpignato | first3 = Carmelo | last4 = Savarino | first4 = Edoardo Vincenzo | last5 = Giron | first5 = Maria Cecilia | journal = Expert Opinion on Drug Metabolism & Toxicology | pages = 1–16 | pmid = 39189409 }}</ref> In April 2024, it was approved for use in South Korea for the treatment of erosive ] (GERD).<ref>{{Cite journal | doi = 10.1007/s40265-024-02057-w | title = Zastaprazan: First Approval | date = 2024 | last1 = Blair | first1 = Hannah A. | journal = Drugs | volume = 84 | issue = 7 | pages = 863–866 | pmid = 38916840 }}</ref> In addition, it is Phase III clinical trials for ] and ].<ref>{{cite web | url = https://adisinsight.springer.com/drugs/800044958 | title = Zastaprazan | publisher = AdisInsight }}</ref>


==References== ==References==

Revision as of 19:01, 23 December 2024

Pharmaceutical compound
Zastaprazan
Clinical data
Trade namesJaqbo
Other namesJP-1366
Legal status
Legal status
  • Rx in South Korea
Identifiers
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC22H26N4O
Molar mass362.477 g·mol
3D model (JSmol)
SMILES
  • CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker. In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). In addition, it is Phase III clinical trials for gastric ulcer and peptic ulcer.

References

  1. Yang, Eunsol; Hwang, Inyoung; Ji, Sang Chun; Kim, John; Lee, Seunghwan (2024). "Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers". CPT: Pharmacometrics & Systems Pharmacology. 13 (12): 2150–2158. doi:10.1002/psp4.13228. PMID 39268835.
  2. Tietto, Angela; Faggin, Sofia; Scarpignato, Carmelo; Savarino, Edoardo Vincenzo; Giron, Maria Cecilia (2024). "Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease". Expert Opinion on Drug Metabolism & Toxicology: 1–16. doi:10.1080/17425255.2024.2397433. PMID 39189409.
  3. Blair, Hannah A. (2024). "Zastaprazan: First Approval". Drugs. 84 (7): 863–866. doi:10.1007/s40265-024-02057-w. PMID 38916840.
  4. "Zastaprazan". AdisInsight.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: